The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Real-world comparison of atezolizumab/bevacizumab vs durvalumab/tremelimumab in decompensated hepatocellular carcinoma.
 
Yu-Han Chen
No Relationships to Disclose
 
Wee Han Ng
No Relationships to Disclose
 
Ting-Hsuan Chiang
No Relationships to Disclose
 
Emily Kaymen
No Relationships to Disclose
 
Natasha Rastogi
No Relationships to Disclose
 
Nguyen Tran
Consulting or Advisory Role - Aptitude Health (Inst); AstraZeneca (Inst); DAVA Oncology (Inst); Elevar Therapeutics (Inst); Exelixis (Inst); Ipsen (Inst); QED Therapeutics (Inst); TEMPUS (Inst)
Speakers' Bureau - DAVA oncology (Inst)
Research Funding - Exact Sciences
 
Yee Hui Yeo
No Relationships to Disclose
 
Ju Dong Yang
No Relationships to Disclose